当前位置： SCI文献检索 > BIOPHARMACEUTICS & DRUG DISPOSITION期刊下所有文献 > Bioavailability of bemetizide and triamterene from a combination formulation.

Bioavailability of bemetizide and triamterene from a combination formulation.

Abstract：

:The bioavailability of the thiazide diuretic bemetizide from a tablet containing 25 mg of this drug and 50 mg of the chemically unrelated diuretic triamterene was lower than, and significantly different (p less than 0.01) from that from a tablet containing 25 mg bemetizide alone. The mean peak plasma level of bemetizide after administration of the combination tablet (68.3 ng ml-1) was lower than that after administration of bemetizide alone (87.9 ng ml-1), although the times of occurrence of the peak levels were similar. The bioavailability of triamterene from the combination tablet was greater than, but not significantly different from that after administration of a capsule containing 50 mg triamterene alone. The mean peak plasma level of triamterene after administration of the combination tablet (44.6 ng ml-1) was higher than and significantly different (p less than 0.001) from that after administration of triamterene alone (15.7 ng ml-1). Although bemetizide is unstable in urine, measurement of the apparent excretion of unchanged drug in the 24 h post-dose urine (less than 4 per cent of the dose) agreed with the estimate of drug bioavailability from the plasma level data. Less than 2 per cent of the dose of triamterene was excreted unchanged in the 24 h post-dose urine, but the urinary excretion data also agreed with the bioavailability estimates from the plasma level data. The results of this study and those reported in the literature suggest that because of their physicochemical properties, the bioavailability of some thiazides and triamterene needs to be evaluated when new formulations of these drugs are produced. However, with respect to the combination formulation reported in this paper, the difference in bioavailability of the thiazide component did not detectably effect the diuretic activity of the formulation.

journal_name

Biopharm Drug Dispos

journal_title

Biopharmaceutics & drug disposition

authors

Brodie RR,Chasseaud LF,Darragh A,Taylor T,Walmsley LM

doi

10.1002/bdd.2510030409

subject

Has Abstract

pub_date

1982-10-01 00:00:00

pages

361-70

issue

eissn

0142-2782

issn

1099-081X

journal_volume

pub_type

临床试验,杂志文章

在线工具

Bioavailability of bemetizide and triamterene from a combination formulation.